Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology, Inc. (KURA) had an affiliate, Brian T. Powl, file a notice of proposed sale of company stock under Rule 144. The notice covers the potential sale of 4,345 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated value of approximately $50,879.95.
The shares were acquired upon the vesting of restricted stock units during the period from 01/26/2025 through 01/26/2026. The notice lists NASDAQ as the trading market and is dated 08/21/2026.
Kura Oncology, Inc. (KURA) reported that Chief Legal Officer Teresa Brophy Bair sold 31,487 shares of common stock on August 19, 2026 in an open-market transaction at a weighted average price of $12.63 per share, with trade prices ranging from $12.44 to $12.83. These shares had been acquired upon vesting of restricted stock units between January 26, 2024 and January 26, 2026. After this sale, she directly holds 195,444 shares of Kura Oncology common stock. The sale was effected under a Rule 10b5-1 trading plan adopted on May 20, 2026.
Kura Oncology, Inc. (KURA) is named as the issuer in a planned resale of its common stock under Rule 144. Officer Teresa Bair filed notice to sell 31,487 shares of Kura common stock through Morgan Stanley Smith Barney LLC. The proposed sale is referenced with a date of 08/19/2026 on the NASDAQ market. The shares were acquired upon vesting of restricted stock units during the period from 01/26/2024 through 01/26/2026.
Kura Oncology, Inc. director and President and CEO Troy Edward Wilson reported a purchase of 100,000 shares of Common Stock on 2026-08-17 at a weighted average price of $11.12 per share, executed in multiple trades between $10.87 and $11.31. The purchased shares are held indirectly by One Fish Two Fish Revocable Trust, bringing that trust’s reported holdings to 379,194 shares following the transaction. Additional reported positions include 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust and 435,456 shares held directly by the reporting person.
Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen report significant ownership stakes in Kura Oncology, Inc. common stock. Montanova Capital and Aaron Cowen each report beneficial ownership of 8,575,422 shares of common stock, representing 9.7% of the class. Averill Master Fund reports beneficial ownership of 7,805,540 shares, representing 8.8% of the class.
All of the securities reported in this Amendment No. 6 are directly owned by advisory clients of Montanova Capital, LLC, with Averill Master Fund, Ltd. being the only client that may be deemed to beneficially own more than 5% of the common stock. Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.
Kura Oncology, Inc. is a commercial-stage biopharmaceutical company focused on precision oncology, now generating its first product revenue from KOMZIFTI (ziftomenib) for relapsed or refractory NPM1-mutated AML in the United States. For the six months ended June 30, 2026, total revenue was $39.1 million, including $14.9 million in KOMZIFTI net product revenue and $24.3 million in collaboration revenue from its global ziftomenib partnership with Kyowa Kirin.
Research and development expenses were $127.2 million, reflecting ongoing ziftomenib combination trials and darlifarnib Phase 1 work, while selling, general and administrative expenses rose to $63.3 million as commercial and corporate infrastructure expanded. Kura reported a net loss of $141.7 million, or $1.60 per share, compared with $123.6 million a year earlier, and used $148.4 million of cash in operating activities in the first half.
Liquidity remains significant, with $70.2 million in cash and cash equivalents and $448.8 million in short-term investments, totaling $519.0 million at June 30, 2026, plus a term loan facility. The company states it believes this balance, together with anticipated $180.0 million in additional Kyowa payments, will fund its current plan into late 2027 and through first topline KOMET-017 results anticipated in 2028.
Kura Oncology reported second quarter 2026 results, highlighting early commercial traction for KOMZIFTI (ziftomenib) in relapsed or refractory NPM1-mutated AML. Net product revenue was $9.1 million, with approximately 115 new patient starts and more than 250 total prescriptions, all growing strongly versus the prior quarter, and KOMZIFTI achieved a majority share of new patient starts in its menin inhibitor class.
Total revenue was $20.9 million, including $11.8 million of collaboration revenue. Kura recorded a net loss of $68.3 million, with R&D expense of $61.9 million and SG&A of $31.8 million. Cash, cash equivalents and short-term investments were $519.0 million as of June 30, 2026, and together with $180 million in anticipated collaboration payments, management expects funding to support the ziftomenib AML program through topline Phase 3 KOMET-017 results anticipated in 2028.
Clinical updates showed high and durable responses for ziftomenib combinations in frontline and relapsed AML, and encouraging activity for darlifarnib combinations across KRAS-mutated tumors and clear cell renal cell carcinoma, supporting its positioning as a precision combination platform and multiple ongoing and planned studies.
Kura Oncology amended and restated executive employment agreements for its Chairman, President and CEO Troy E. Wilson, Chief Commercial Officer Brian Powl and Chief Operating Officer Kathleen Ford to modify severance protections, including change‑of‑control terms tied to a Corporate Transaction.
If Wilson is terminated without Cause or resigns for Good Reason outside the Corporate Transaction window, he receives a lump sum equal to 12 months base salary, up to 12 months COBRA premiums and a 12‑month stock option exercise period. If the separation occurs within 59 days before, on, or within 18 months after a Corporate Transaction, his cash severance increases to 24 months salary plus 200% of target bonus, with up to 24 months COBRA, full equity vesting at target and a 12‑month option exercise period. Powl and Ford receive similar protections, with 12 months salary outside a Corporate Transaction and, within the transaction window, 18 months salary, 150% of target bonus, extended COBRA, full equity vesting and a 12‑month option exercise period.
Kura Oncology, Inc. Chief Medical Officer Mollie Leoni sold 84,929 shares of common stock in an open-market transaction on June 18, 2026 at a weighted average price of $9.8233 per share. The trades were executed in multiple lots at prices ranging from $9.56 to $9.98.
The shares sold had been acquired upon vesting of restricted stock units and performance restricted stock units between January 26, 2022 and January 26, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Following this transaction, Leoni directly holds 182,345 Kura Oncology shares.